News

Shares of AstraZeneca PLC AZN shed 1.66% to £104.50 Friday, on what proved to be an all-around dismal trading session for the ...
AstraZeneca’s stock market exit would be devastating blow, warns ex-chancellor - The UK is ‘a hostile environment’ for ...
This was the ADR's fourth consecutive day of gains.
AstraZeneca PLC (NASDAQ:AZN) is one of the 10 best defensive stocks to buy in a volatile market. On July 4, the company ...
AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...
AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...
AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...
AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...
The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...
Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...
Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.
See the latest AstraZeneca PLC ADR stock price (AZN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.